Abstract
Intravenous bisphosphonates are a standard therapeutic option in the prevention of skeletal-related events in metastatic breast and prostate cancer as well as multiple myeloma with bone involvement. Denosumab represents a new class of medications that inhibits the RANK ligand and is currently being evaluated to prevent skeletal-related events.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have